MicroRNAs in colorectal cancer: Small molecules with big functions

Cancer Letters

Volumn 360, Issue 2, 2015, Pages 89-105

  Xuan, Yu ^a,b   Yang, Huiliang ^b   Zhao, Linjie ^b   Lau, Wayne Bond ^c   Lau, Bonnie ^d   Ren, Ning ^a   Hu, Yuehong ^a   Yi, Tao ^a   Zhao, Xia ^a   Zhou, Shengtao ^a   Wei, Yuquan ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Colorectal cancer; MicroRNA; Oncogene; Tumor suppressor

Indexed keywords

CETUXIMAB; MICRORNA; MICRORNA 101; MICRORNA 107; MICRORNA 126; MICRORNA 133; MICRORNA 137; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 16; MICRORNA 195; MICRORNA 200; MICRORNA 200B; MICRORNA 200C; MICRORNA 214; MICRORNA 215; MICRORNA 30; MICRORNA 34; MICRORNA 342; MICRORNA 345; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; MICRORNA 365; MICRORNA 491; PANITUMUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; COLON CARCINOGENESIS; COLORECTAL CANCER; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; HUMAN; METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SHORT SURVEY; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UPREGULATION; COLORECTAL TUMOR; GENETICS;

COLORECTAL NEOPLASMS; HUMANS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL;

EID: 84924858306     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.051     Document Type: Review

References (189)

1. Valeri N., Croce C.M., Fabbri M. Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics Proteomics 2009, 6:195-204.
2. Forman J.J., Legesse-Miller A., Coller H.A. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14879-14884.
3. Iorio M.V., Croce C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med 2012, 4:143-159.
4. Bhayani M.K., Calin G.A., Lai S.Y. Functional relevance of miRNA sequences in human disease. Mutat. Res 2012, 731:14-19.
5. Garofalo M., Croce C.M. MicroRNAs: master regulators as potential therapeutics in cancer, in: A.K. Cho (Ed.). Ann. Rev. Pharmacol. Toxicol 2011, 51:25-43.
6. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genetics 2010, 11:597-610.
7. Zhao L.Q., Chen X., Cao Y. New role of microRNA: carcinogenesis and clinical application in cancer. Acta Biochim. Biophys. Sin. (Shanghai) 2011, 43:831-839.
8. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:15524-15529.
9. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
10. Meng F., Henson R., Lang M., Wehbe H., Maheshwari S., Mendell J.T., et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129.
11. Chen F., Zhu H.H., Zhou L.F., Wu S.S., Wang J., Chen Z. Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol. Rep 2010, 23:1457-1462.
12. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F., et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther 2008, 7:2152-2159.
13. Xia L., Zhang D., Du R., Pan Y., Zhao L., Sun S., et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123:372-379.
14. Nie J., Liu L., Zheng W., Chen L., Wu X., Xu Y.X., et al. MicroRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting cyclin D1 and Bcl-2. Carcinogenesis 2012, 33:220-225.
15. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
16. Motoyama K., Inoue H., Takatsuno Y., Tanaka F., Mimori K., Uetake H., et al. Over- and under-expressed microRNAs in human colorectal cancer. Int. J. Oncol 2009, 34:1069-1075.
17. Tsang W.P., Kwok T.T. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 2009, 30:953-959.
18. Olive V., Bennett M.J., Walker J.C., Ma C., Jiang I., Cordon-Cardo C., et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009, 23:2839-2849.
19. Mu P., Han Y.C., Betel D., Yao E., Squatrito M., Ogrodowski P., et al. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 2009, 23:2806-2811.
20. Schee K., Boye K., Abrahamsen T.W., Fodstad O., Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 2012, 12:505.
21. Chai H., Liu M., Tian R., Li X., Tang H. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim. Biophys. Sin. (Shanghai) 2011, 43:217-225.
22. Tsuchida A., Ohno S., Wu W., Borjigin N., Fujita K., Aoki T., et al. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 2011, 102:2264-2271.
23. Dews M., Homayouni A., Yu D., Murphy D., Sevignani C., Wentzel E., et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet 2006, 38:1060-1065.
24. Nagel R., le Sage C., Diosdado B., van der Waal M., Vrielink J., Bolijn A., et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008, 68:5795-5802.
25. Iorio M.V., Croce C.M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol 2009, 27:5848-5856.
26. Biswas S., Trobridge P., Romero-Gallo J., Billheimer D., Myeroff L.L., Willson J.K., et al. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Genes Chromosomes Cancer 2008, 47:95-106.
27. Sanders M.A., Majumdar A.P. Colon cancer stem cells: implications in carcinogenesis. Front. Biosci 2011, 16:1651-1662.
28. Gabriely G., Wurdinger T., Kesari S., Esau C.C., Burchard J., Linsley P.S., et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol 2008, 28:5369-5380.
29. Krichevsky A.M., Gabriely G. miR-21: a small multi-faceted RNA. J. Cell. Mol. Med 2009, 13:39-53.
30. Luo X.Y., Burwinkel B., Tao S., Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer?. Cancer Epidemiol. Biomarkers Prev 2011, 20:1272-1286.
31. Cottonham C.L., Kaneko S., Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J. Biol. Chem 2010, 285:35293-35302.
32. Brunet Vega A., Pericay C., Moya I., Ferrer A., Dotor E., Pisa A., et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol. Rep 2013, 30:320-326.
33. Tang W., Zhu Y., Gao J., Fu J., Liu C., Liu Y., et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Br. J. Cancer 2014, 110:450-458.
34. Huang Z.H., Huang D., Ni S.J.A., Peng Z.L., Sheng W.Q., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 2010, 127:118-126.
35. Wang Y.X., Zhang X.Y., Zhang B.F., Yang C.Q., Chen X.M., Gao H.J. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J. Dig. Dis 2010, 11:50-54.
36. Wang B.D., Kline C.L.B., Pastor D.M., Olson T.L., Frank B., Luu T., et al. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappa B and microRNA network. Mol. Cancer 2010, 9.
37. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med 2011, 17:211-215.
38. Sachdeva M., Mo Y.Y. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010, 70:378-387.
39. Braun C.J., Zhang X., Savelyeva I., Wolff S., Moll U.M., Schepeler T., et al. p53-Responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008, 68:10094-10104.
40. Huang Z.M., Yang J., Shen X.Y., Zhang X.Y., Meng F.S., Xu J.T., et al. MicroRNA expression profile in non-cancerous colonic tissue associated with lymph node metastasis of colon cancer. J. Dig. Dis 2009, 10:188-194.
41. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9:582-589.
42. Shell S., Park S.M., Radjabi A.R., Schickel R., Kistner E.O., Jewell D.A., et al. Let-7 expression defines two differentiation stages of cancer. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11400-11405.
43. Takahashi M., Sung B., Shen Y., Hur K., Link A., Boland C.R., et al. Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis 2012, 33:2441-2449.
44. Peter M.E. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009, 8:843-852.
45. Dong Y., Wu W.K., Wu C.W., Sung J.J., Yu J., Ng S.S. MicroRNA dysregulation in colorectal cancer: a clinical perspective. Br. J. Cancer 2011, 104:893-898.
46. Creighton C.J., Casa A., Lazard Z., Huang S.X., Tsimelzon A., Hilsenbeck S.G., et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J. Clin. Oncol 2008, 26:4078-4085.
47. Yu T., Wang X.Y., Gong R.G., Li A., Yang S., Cao Y.T., et al. The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J. Exp. Clin. Cancer Res 2009, 28:64.
48. Jazbutyte V., Thum T. MicroRNA-21: from cancer to cardiovascular disease. Curr. Drug Targets 2010, 11:926-935.
49. Wu W.K.K., Law P.T.Y., Lee C.W., Cho C.H., Fan D.M., Wu K.C., et al. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 2011, 32:247-253.
50. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol 2009, 11:1487-1495.
51. Yu L., Todd N.W., Xing L., Xie Y., Zhang H., Liu Z., et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 2010, 127:2870-2878.
52. Sachdeva M., Liu Q., Cao J., Lu Z., Mo Y.Y. Negative regulation of miR-145 by C/EBP-beta through the Akt pathway in cancer cells. Nucleic Acids Res 2012, 40:6683-6692.
53. Asangani I.A., Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
54. Isaksson-Mettavainio M., Palmqvist R., Forssell J., Stenling R., Oberg A. SMAD4/DPC4 expression and prognosis in human colorectal cancer. Anticancer Res 2006, 26:507-510.
55. Dupont S., Mamidi A., Cordenonsi M., Montagner M., Zacchigna L., Adorno M., et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009, 136:123-135.
56. Tsang W.P., Ng E.K., Ng S.S., Jin H., Yu J., Sung J.J., et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 2010, 31:350-358.
57. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
58. Beezhold K., Liu J., Kan H., Meighan T., Castranova V., Shi X., et al. miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis. Toxicol. Sci 2011, 123:411-420.
59. Liu J., Weiss H.L., Rychahou P., Jackson L.N., Evers B.M., Gao T. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene 2009, 28:994-1004.
60. Huang Z., Huang S., Wang Q., Liang L., Ni S., Wang L., et al. MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res 2011, 71:2582-2589.
61. Sun K., Wang W., Zeng J.J., Wu C.T., Lei S.T., Li G.X. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol. Sin 2011, 32:375-384.
62. Bartels C.L., Tsongalis G.J. MicroRNAs: novel biomarkers for human cancer. Clin. Chem 2009, 55:623-631.
63. Lu Z., Liu M., Stribinskis V., Klinge C.M., Ramos K.S., Colburn N.H., et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008, 27:4373-4379.
64. Baffa R., Fassan M., Volinia S., O'Hara B., Liu C.G., Palazzo J.P., et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol 2009, 219:214-221.
65. Chen H.Y., Lin Y.M., Chung H.C., Lang Y.D., Lin C.J., Huang J., et al. miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 2012, 72:3631-3641.
66. Yamakuchi M., Lotterman C.D., Bao C., Hruban R., Karim B., Mendell J.T., et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6334-6339.
67. Valeri N., Gasparini P., Fabbri M., Braconi C., Veronese A., Lovat F., et al. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6982-6987.
68. Ovcharenko D., Kelnar K., Johnson C., Leng N., Brown D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res 2007, 67:10782-10788.
69. Li X., Wang Q.H., Zheng Y., Lv S., Ning S.W., Sun J., et al. Prioritizing human cancer microRNAs based on genes' functional consistency between microRNA and cancer. Nucleic Acids Res 2011, 39.
70. Borralho P.M., Kren B.T., Castro R.E., da Silva I.B., Steer C.J., Rodrigues C.M. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J. 2009, 276:6689-6700.
71. Luo H., Zou J., Dong Z., Zeng Q., Wu D., Liu L. Up-regulated miR-17 promotes cell proliferation, tumour growth and cell cycle progression by targeting the RND3 tumour suppressor gene in colorectal carcinoma. Biochem. J. 2012, 442:311-321.
72. Takayama T., Miyanishi K., Hayashi T., Sato Y., Niitsu Y. Colorectal cancer: genetics of development and metastasis. J. Gastroenterol 2006, 41:185-192.
73. Patel B.B., Yu Y., Du J., Levi E., Phillip P.A., Majumdar A.P. Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with adenomas: a risk factor for colon cancer. Biochem. Biophys. Res. Commun 2009, 378:344-347.
74. Papachristou D.J., Korpetinou A., Giannopoulou E., Antonacopoulou A.G., Papadaki H., Grivas P., et al. Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas. Virchows Arch 2011, 459:431-440.
75. Bandres E., Agirre X., Bitarte N., Ramirez N., Zarate R., Roman-Gomez J., et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int. J. Cancer 2009, 125:2737-2743.
76. Ozsolak F., Poling L.L., Wang Z., Liu H., Liu X.S., Roeder R.G., et al. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008, 22:3172-3183.
77. Hurst D.R., Edmonds M.D., Welch D.R. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 2009, 69:7495-7498.
78. Lujambio A., Calin G.A., Villanueva A., Ropero S., Sanchez-Cespedes M., Blanco D., et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13556-13561.
79. Lopez-Camarillo C., Marchat L.A., Arechaga-Ocampo E., Perez-Plasencia C., Del Moral-Hernandez O., Castaneda-Ortiz E.J., et al. MetastamiRs: non-coding microRNAs driving cancer invasion and metastasis. Int. J. Mol. Sci 2012, 13:1347-1379.
80. Yamamichi N., Shimomura R., Inada K.I., Sakurai K., Haraguchi T., Ozaki Y., et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin. Cancer Res 2009, 15:4009-4016.
81. Riou P., Villalonga P., Ridley A.J. Rnd proteins: multifunctional regulators of the cytoskeleton and cell cycle progression. Bioessays 2010, 32:986-992.
82. Melo S.A., Kalluri R. Angiogenesis is controlled by miR-27b associated with endothelial tip cells. Blood 2012, 119:2439-2440.
83. Zhou Q.B., Gallagher R., Ufret-Vincenty R., Li X.Y., Olson E.N., Wang S.S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23 similar to 27 similar to 24 clusters. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:8287-8292.
84. Koga Y., Yasunaga M., Takahashi A., Kuroda J., Moriya Y., Akasu T., et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev. Res 2010, 3:1435-1442.
85. Dong Q., Meng P., Wang T., Qin W., Wang F., Yuan J., et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS ONE 2010, 5:e10147.
86. Shimizu S., Takehara T., Hikita H., Kodama T., Miyagi T., Hosui A., et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J. Hepatol 2010, 52:698-704.
87. Ruzzo A., Graziano F., Vincenzi B., Canestrari E., Perrone G., Galluccio N., et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 2012, 17:823-829.
88. Tol J., Nagtegaal I.D., Punt C.J. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med 2009, 361:98-99.
89. Earle J.S., Luthra R., Romans A., Abraham R., Ensor J., Yao H., et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J. Mol. Diagn 2010, 12:433-440.
90. Akao Y., Nakagawa Y., Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol. Pharm. Bull 2006, 29:903-906.
91. Mekenkamp L.J., Tol J., Dijkstra J.R., de Krijger I., Vink-Borger M.E., van Vliet S., et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer 2012, 12:292.
92. Kjersem J.B., Ikdahl T., Guren T., Skovlund E., Sorbye H., Hamfjord J., et al. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. BMC Cancer 2012, 12:534.
93. Graziano F., Canestrari E., Loupakis F., Ruzzo A., Galluccio N., Santini D., et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. 2010, 10:458-464.
94. Zhang W., Winder T., Ning Y., Pohl A., Yang D., Kahn M., et al. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann. Oncol 2011, 22:104-109.
95. Marson A., Levine S.S., Cole M.F., Frampton G.M., Brambrink T., Johnstone S., et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008, 134:521-533.
96. Suzuki H., Takatsuka S., Akashi H., Yamamoto E., Nojima M., Maruyama R., et al. Genome-wide profiling of chromatin signatures reveals epigenetic regulation of microRNA genes in colorectal cancer. Cancer Res 2011, 71:5646-5658.
97. Toyota M., Suzuki H., Sasaki Y., Maruyama R., Imai K., Shinomura Y., et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008, 68:4123-4132.
98. Lodygin D., Tarasov V., Epanchintsev A., Berking C., Knyazeva T., Korner H., et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
99. Yamakuchi M., Ferlito M., Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13421-13426.
100. Slaby O., Svoboda M., Fabian P., Smerdova T., Knoflickova D., Bednarikova M., et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007, 72:397-402.
101. Zhang H., Cai X., Wang Y., Tang H., Tong D., Ji F. MicroRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol. Rep 2010, 24:1363-1369.
102. Chen X., Guo X., Zhang H., Xiang Y., Chen J., Yin Y., et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009, 28:1385-1392.
103. Ng E.K., Tsang W.P., Ng S.S., Jin H.C., Yu J., Li J.J., et al. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br. J. Cancer 2009, 101:699-706.
104. Yang Y., Chaerkady R., Kandasamy K., Huang T.C., Selvan L.D., Dwivedi S.B., et al. Identifying targets of miR-143 using a SILAC-based proteomic approach. Mol. Biosyst 2010, 6:1873-1882.
105. Xu Q., Liu L.Z., Qian X., Chen Q., Jiang Y., Li D., et al. miR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012, 40:761-774.
106. Akao Y., Nakagawa Y., Hirata I., Iio A., Itoh T., Kojima K., et al. Role of anti-oncomirs miR-143 and-145 in human colorectal tumors. Cancer Gene Ther 2010, 17:398-408.
107. Gregersen L.H., Jacobsen A.B., Frankel L.B., Wen J.Y., Krogh A., Lund A.H. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS ONE 2010, 5.
108. Zhang J.J., Guo H.Y., Zhang H., Wang H.B., Qian G.X., Fan X.Q., et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene friend leukemia virus integration 1 gene. Cancer 2011, 117:86-95.
109. La Rocca G., Badin M., Shi B., Xu S.Q., Deangelis T., Sepp-Lorenzinoi L., et al. Mechanism of growth inhibition by microRNA 145: the role of the IGF-I receptor signaling pathway. J. Cell. Physiol 2009, 220:485-491.
110. Shi B., Sepp-Lorenzino L., Prisco M., Linsley P., DeAngelis T., Baserga R. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J. Biol. Chem 2007, 282:32582-32590.
111. Sachdeva M., Zhu S., Wu F., Wu H., Walia V., Kumar S., et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3207-3212.
112. Arndt G.M., Dossey L., Cullen L.M., Lai A., Druker R., Eisbacher M., et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009, 9.
113. Ma Y.L., Zhang P., Wang F., Moyer M.P., Yang J.J., Liu Z.H., et al. Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b. J. Cell. Mol. Med 2011, 15:1941-1954.
114. Van Cutsem E., Kohne C.H., Lang I., Folprecht G., Nowacki M.P., Cascinu S., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol 2011, 29:2011-2019.
115. Grady W.M., Parkin R.K., Mitchell P.S., Lee J.H., Kim Y.H., Tsuchiya K.D., et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 2008, 27:3880-3888.
116. Guo C.G., Sah J.F., Beard L., Willson J.K.V., Markowitz S.D., Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 2008, 47:939-946.
117. Papetti M., Augenlicht L.H. Mybl2, downregulated during colon epithelial cell maturation, is suppressed by miR-365. Am. J. Physiol. Gastrointest. Liver Physiol 2011, 301:G508-G518.
118. Tang J.T., Wang J.L., Du W., Hong J., Zhao S.L., Wang Y.C., et al. MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer. Carcinogenesis 2011, 32:1207-1215.
119. Baraniskin A., Birkenkamp-Demtroder K., Maghnouj A., Zollner H., Munding J., Klein-Scory S., et al. miR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 2012, 33:732-739.
120. McGuire J.J. Anticancer antifolates: current status and future directions. Curr. Pharm. Des 2003, 9:2593-2613.
121. Mishra P.J., Song B., Wang Y., Humeniuk R., Banerjee D., Merlino G., et al. miR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS ONE 2009, 4.
122. Slaby O., Svoboda M., Michalek J., Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol. Cancer 2009, 8:102.
123. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26:745-752.
124. Boni V., Bitarte N., Cristobal I., Zarate R., Rodriguez J., Maiello E., et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol. Cancer Ther 2010, 9:2265-2275.
125. Georges S.A., Biery M.C., Kim S.Y., Schelter J.M., Guo J., Chang A.N., et al. Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res 2008, 68:10105-10112.
126. Wang H., Wu J., Meng X., Ying X., Zuo Y., Liu R., et al. MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis 2011, 32:1033-1042.
127. Liu L., Chen L., Xu Y.X., Li R., Du X.H. MicroRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem. Biophys. Res. Commun 2010, 400:236-240.
128. Nakano H., Miyazawa T., Kinoshita K., Yamada Y., Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int. J. Cancer 2010, 127:1072-1080.
129. Lima R.T., Busacca S., Almeida G.M., Gaudino G., Fennell D.A., Vasconcelos M.H. MicroRNA regulation of core apoptosis pathways in cancer. Eur. J. Cancer 2011, 47:163-174.
130. Hu G., Chen D.J., Li X.R., Yang K.Y., Wang H.X., Wu W. miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol. Ther 2010, 10:190-197.
131. van Mil A., Grundmann S., Goumans M.J., Lei Z.Y., Oerlemans M.I., Jaksani S., et al. MicroRNA-214 inhibits angiogenesis by targeting quaking and reducing angiogenic growth factor release. Cardiovas Res 2012, 93:655-665.
132. Chamorro-Jorganes A., Araldi E., Penalva L.O.F., Sandhu D., Fernandez-Hernando C., Suarez Y. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler. Thromb. Vasc. Biol 2011, 31:2595-2606.
133. Nayak S., Herzog R.W. Progress and prospects: immune responses to viral vectors. Gene Ther 2010, 17:295-304.
134. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol 2010, 28:341-347.
135. Su J., Baigude H., McCarroll J., Rana T.M. Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Res 2011, 39:e38.
136. Liu C., Tang D.G. MicroRNA regulation of cancer stem cells. Cancer Res 2011, 71:5950-5954.
137. Wang Y., Yu Y., Tsuyada A., Ren X., Wu X., Stubblefield K., et al. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011, 30:1470-1480.
138. Stenvang J., Silahtaroglu A.N., Lindow M., Elmen J., Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin. Cancer Biol 2008, 18:89-102.
139. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol 2008, 26:561-569.
140. De Guire V., Caron M., Scott N., Menard C., Gaumont-Leclerc M.F., Chartrand P., et al. Designing small multiple-target artificial RNAs. Nucleic Acids Res 2010, 38:e140.
141. Wang W., Sun K., Wu C.T., Lei S.T., Zeng J.J., Wu Y.J., et al. Effect of miR-221-specific inhibitor on the proliferation and apoptosis of human colorectal carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao 2011, 31:674-677.
142. Balaguer F., Moreira L., Lozano J.J., Link A., Ramirez G., Shen Y., et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin. Cancer Res 2011, 17:6239-6249.
143. Balaguer F., Link A., Lozano J.J., Cuatrecasas M., Nagasaka T., Boland C.R., et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 2010, 70:6609-6618.
144. Ibrahim A.F., Weirauch U., Thomas M., Grunweller A., Hartmann R.K., Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011, 71:5214-5224.
145. Wu C.W., Ng S.S.M., Dong Y.J., Ng S.C., Leung W.W., Lee C.W., et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012, 61:739-745.
146. Misawa A., Katayama R., Koike S., Tomida A., Watanabe T., Fujita N. AP-1-dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncol. Res 2010, 19:23-33.
147. Weiler J., Hunziker J., Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?. Gene Ther 2006, 13:496-502.
148. Pritchard C.C., Kroh E., Wood B., Arroyo J.D., Dougherty K.J., Miyaji M.M., et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res 2012, 5:492-497.
149. Yi J.M., Dhir M., Van Neste L., Downing S.R., Jeschke J., Glockner S.C., et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin. Cancer Res 2011, 17:1535-1545.
150. Ragusa M., Majorana A., Statello L., Maugeri M., Salito L., Barbagallo D., et al. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol. Cancer Ther 2010, 9:3396-3409.
151. Monzo M., Navarro A., Bandres E., Artells R., Moreno I., Gel B., et al. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res 2008, 18:823-833.
152. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
153. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
154. Michael A., Bajracharya S.D., Yuen P.S., Zhou H., Star R.A., Illei G.G., et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis 2010, 16:34-38.
155. Park N.J., Zhou H., Elashoff D., Henson B.S., Kastratovic D.A., Abemayor E., et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res 2009, 15:5473-5477.
156. Xie Y., Todd N.W., Liu Z., Zhan M., Fang H., Peng H., et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010, 67:170-176.
157. Link A., Balaguer F., Shen Y., Nagasaka T., Lozano J.J., Boland C.R., et al. Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers Prev 2010, 19:1766-1774.
158. Schepeler T., Reinert J.T., Ostenfeld M.S., Christensen L.L., Silahtaroglu A.N., Dyrskjot L., et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008, 68:6416-6424.
159. Qu K.Z., Zhang K., Li H., Afdhal N.H., Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J. Clin. Gastroenterol 2011, 45:355-360.
160. Barkan D., Green J.E., Chambers A.F. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur. J. Cancer 2010, 46:1181-1188.
161. Carmona F.J., Esteller M. Moving closer to a prognostic DNA methylation signature in colon cancer. Clin. Cancer Res 2011, 17:1215-1217.
162. Smits K.M., Paranjape T., Nallur S., Wouters K.A., Weijenberg M.P., Schouten L.J., et al. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin. Cancer Res 2011, 17:7723-7731.
163. Rosenfeld N., Aharonov R., Meiri E., Rosenwald S., Spector Y., Zepeniuk M., et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol 2008, 26:462-469.
164. Day E.O., Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010, 12:201.
165. de Planell-Saguer M., Rodicio M.C., Mourelatos Z. Rapid in situ codetection of noncoding RNAs and proteins in cells and formalin-fixed paraffin-embedded tissue sections without protease treatment. Nat. Protoc 2010, 5:1061-1073.
166. Gentner B., Schira G., Giustacchini A., Amendola M., Brown B.D., Ponzoni M., et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat. Methods 2009, 6:63-66.
167. Hanke M., Hoefig K., Merz H., Feller A.C., Kausch I., Jocham D., et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol 2010, 28:655-661.
168. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol 2008, 110:13-21.
169. Frenzel A., Grespi F., Chmelewskij W., Villunger A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 2009, 14:584-596.
170. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res 2009, 15:1126-1132.
171. Jiang B.H., Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat 2008, 11:63-76.
172. Woods K., Thomson J.M., Hammond S.M. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J. Biol. Chem 2007, 282:2130-2134.
173. Diosdado B., van de Wiel M.A., Terhaar Sive Droste J.S., Mongera S., Postma C., Meijerink W.J., et al. miR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br. J. Cancer 2009, 101:707-714.
174. Liebig T., Erasmus J., Kalaji R., Davies D., Loirand G., Ridley A., et al. RhoE is required for keratinocyte differentiation and stratification. Mol. Biol. Cell 2009, 20:452-463.
175. Xiang J., Wu J. Feud or friend? The role of the miR-17-92 cluster in tumorigenesis. Curr. Genomics 2010, 11:129-135.
176. Leupold J.H., Yang H.S., Colburn N.H., Asangani I., Post S., Allgayer H. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 2007, 26:4550-4562.
177. Kumar M.S., Lu J., Mercer K.L., Golub T.R., Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet 2007, 39:673-677.
178. Muppala S., Mudduluru G., Leupold J.H., Buergy D., Sleeman J.P., Allgayer H. CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a. PLoS ONE 2013, 8:e59563.
179. Yu Y., Kanwar S.S., Patel B.B., Oh P.S., Nautiyal J., Sarkar F.H., et al. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis 2012, 33:68-76.
180. Li X., Wang Y., Sharif-Afshar A.R., Uwamariya C., Yi A., Ishii K., et al. Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling. Differentiation 2009, 77:95-102.
181. Yu Y., Sarkar F.H., Majumdar A.P. Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl. Oncol 2013, 6:180-186.
182. Liu X., Zhang Z., Sun L., Chai N., Tang S., Jin J., et al. MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis 2011, 32:1798-1805.
183. Martello G., Rosato A., Ferrari F., Manfrin A., Cordenonsi M., Dupont S., et al. A microRNA targeting dicer for metastasis control. Cell 2010, 141:1195-1207.
184. Faber C., Horst D., Hlubek F., Kirchner T. Overexpression of Dicer predicts poor survival in colorectal cancer. Eur. J. Cancer 2011, 47:1414-1419.
185. Ma L., Young J., Prabhala H., Pan E., Mestdagh P., Muth D., et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol 2010, 12:247-256.
186. Chen Y., Zhu X., Zhang X., Liu B., Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther 2010, 18:1650-1656.
187. Schetter A.J., Harris C.C. Plasma microRNAs: a potential biomarker for colorectal cancer?. Gut 2009, 58:1318-1319.
188. Nuovo G., Lee E.J., Lawler S., Godlewski J., Schmittgen T. In situ detection of mature microRNAs by labeled extension on ultramer templates. Biotechniques 2009, 46:115-126.
189. Schulte J.H., Marschall T., Martin M., Rosenstiel P., Mestdagh P., Schlierf S., et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res 2010, 38:5919-5928.